Federal Register #2026-06501

NIAID Offers Licensing of Government-Owned Antibody Technology for Therapeutic Applications

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) under the Department of Health and Human Services (HHS), is offering a government-owned antibody technology for licensing and collaborative research. - Government Buyer: - National Institute of Allergy and Infectious Diseases (NIAID) - National Institutes of Health (NIH) - Department of Health and Human Services (HHS) - Technology Offered: - Fully human antibodies with anti-lymphocyte specificities and lytic activity - Includes a potent antibody designated NIH58.9 - Applications: monoclonal antibody therapies, bispecific antibodies, antibody-drug conjugates - Intended uses: organ transplantation, B-cell lymphomas, autoimmune conditions - Technology stage: pre-clinical - Intellectual property: HHS Reference No. E0252025, U.S. Provisional Patent Application 63/787,190 - Unique Requirements: - Opportunity for licensing or collaborative research - No commercial OEMs or vendors named; technology developed by NIAID researchers - Focus on commercialization of federally funded research

Description

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), announces the availability of certain government-owned inventions for licensing to promote commercialization of federally funded research. The notice highlights a new technology involving fully human antibodies with anti-lymphocyte specificities and lytic activity, which have potential applications in treating B-cell cancers and autoimmune diseases. Interested parties may license the technology or engage in collaborative research to further develop and commercialize these inventions.

View original listing